SAMM 823

Test Report No.: VX-TR-25-0454
Copy No.: 1

DETERMINATION OF THE VIRUCIDAL ACTIVITY (EN 14476) OF BERRYC SANITIZER

Method:	EN 14476:2013+A2:2019 (E) Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity in the medical area – Test method and requirements (phase 2, step 1)
Client:	TEVO Creations Sdn. Bhd. No. 2, Lorong Beringin 1 Taman Industri Beringin 14100 Simpang Ampat, Pulau Pinang Malaysia
Testing Laboratory:	Viroxy Sdn. Bhd. 6th Floor, Menara RKT 36, Jalan Raja Abdullah 50300 Kuala Lumpur Malaysia

Kuala Lumpur, 26 September 2025

Dr Syazani Suhaimi
Microbiologist

Viroxy Sdn. Bhd. (1193371-A)
6th Floor · Menara RKT · 36 Jalan Raja Abdullah · 50300 Kuala Lumpur · Malaysia
Phone: +60 (0)3 2630 8888 · info@viroxy.com
www.viroxy.com

Sample Identification			
Sample name	BerryC Sanitizer		
Lab no.	VX-63-25-0002		
Batch no.	Not Specified		
Product appearance	Clear, pink solution		
Manufacturer	TEVO Creations Sdn. Bhd. No. 2, Lorong Beringin 1 Taman Industri Beringin 14100 Simpang Ampat, Pulau Pinang Malaysia		
Active substance(s)	BKC		
Sample receipt date	17 September 2025		
Storage condition(s)	Room temperature		
Product diluent	Not applicable; ready-to-use-product		
Experimental Conditions			
Testing period	19 September 2025 - 23 September 2025		
Virus strain	*Vaccinia virus*, strain Ankara, ATCC VR-1508	Passage no.	P2
Cell line	BHK-21 cells, ATCC CCL-10	Passage no.	P14
Cell culture medium	EMEM with 2% FBS		
Concentration(s)	100.00* %		
Contact time(s)	0.5, 1, 5 and 30 minutes		
Interfering substance	0.30 g/L bovine albumin solution		
Test temperature	20 °C ± 1 °C		
Incubation conditions	5 days, 36 °C ± 1 °C		
Test Method and its Validation			
Testing Method	Quantal test		
Inactivation method	Immediate dilution Molecular sieving using MicroSpinTM S 400 HR		
Reference substance	Formaldehyde		

Verification of Results	
Passing criteria	The virus control test suspension has a titre of at least 10^8 $TCID_{50}$/mL, which is high enough to verify the method by allowing for a 4 log_{10} reduction. The detectable titre reduction must be at least 4 log_{10}.
Cytotoxicity	Cytotoxicity of the product test solution does not affect cell morphology and growth or susceptibility for the test organism in the dilutions of the test mixtures which are necessary to demonstrate a 4-log reduction of the virus
Cells sensitivity to virus	Comparative virus titration on cells cultures treated with test mixture dilutions and in parallel with PBS (cell susceptibility control) result in a difference of <1 log of virus titre
Suppression disinfectant activity	The difference to the test suspension in the control of efficiency for suppression of product's activity shall be ⩽0.5 log
Reference control	The difference between the logarithmic titre of the virus control and the logarithmic titre of the test organism in the reference inactivation test is: Between -0.5 & -2.5 after 30 minutes; between -2 & -4.5 after 60 minutes for *poliovirus* Between -3 and -5 after 30 minutes; between -3.5 and -5.5 after 60 minutes for *adenovirus* Between -1 and -3 after 30 minutes; between -2 and -4 after 60 minutes for *murine norovirus* Between 0.0 and -2.0 after 30 minutes; between -0.5 and -2.5 after 60 minutes for *parvovirus* Between -0.75 and -3.5 after 5 minutes; between -2.0 and ⩾-4.0 after 15 minutes for *vacciniavirus*

Results

Test organism: *Vaccinia virus*, strain Ankara, ATCC VR-1508

Test concentration (%) / contact time (min)	Virus control, V_C	Cytotoxicity effect, CE	Average reduction, lg R	Percentage reduction (%)	Associated risk†
100.00* / 0.5	V_{C1}: 6.75 ± 0.33 V_{C2}: 6.88 ± 0.37	CE: 2.50 ± 0.00	lg R: **≥4.32 ± 0.26**	**≥99.99**	Minimal risk of false acceptance
100.00* / 1	V_{C1}: 6.75 ± 0.33 V_{C2}: 6.88 ± 0.37	CE: 2.50 ± 0.00	lg R: **≥4.32 ± 0.26**	**≥99.99**	Minimal risk of false acceptance
100.00* / 5	V_{C1}: 6.75 ± 0.33 V_{C2}: 6.88 ± 0.37	CE: 2.50 ± 0.00	lg R: **≥4.32 ± 0.267**	**≥99.99**	Minimal risk of false acceptance
100.00* / 30	V_{C1}: 6.75 ± 0.33 V_{C2}: 6.88 ± 0.37	CE: 2.50 ± 0.00	lg R: **≥4.32 ± 0.267**	**≥99.99**	Minimal risk of false acceptance

* The product can only be tested at 80.00 % concentration or less, as some dilution always occurs when test organisms and interfering substance are added.

Conclusions

BerryC Sanitizer showed the required viral reduction of ≥4.0 $\log_{10}$ against test strain *Vaccinia virus*, strain Ankara, ATCC VR-1508 in accordance with EN 14476:2013+A2:2019 (E) at 100.00* % concentration(s) after 0.5, 1, 5 and 30 minutes under the stated condition. According to the simple acceptance decision rule†, there is a minimal risk of false acceptance.

Note

Virucidal activity – the capability of a product to produce a reduction in the number of viable viruses belonging to reference strains under defined conditions by at least 4 orders (10^4).

$R = V_C/N_a$ = the reduction in viability, or $\lg R = \lg V_C - \lg N_a$

* The product can only be tested at 80.00 % concentration or less, as some dilution always occurs when test organisms and interfering substance are added.

† The decision rule applied is simple acceptance rule with no guard band and up to 50 % risk of false acceptance or rejection. This rule has been determined by the laboratory and agreed with the client prior to testing

TEVO Creations Sdn. Bhd.
No. 2, Lorong Beringin 1
Taman Industri Beringin
14100 Simpang Ampat, Pulau Pinang
Malaysia

EXPERT OPINION*

This expert opinion is based on the test report VX-TR-25-0454 dated 26 September 2025.

The virucidal activity of the disinfectant BerryC Sanitizer of TEVO Creations Sdn. Bhd. against *Vaccinia virus*, strain Ankara, ATCC VR-1508 was investigated by a quantitative suspension test according to EN 14476:2013+A2:2019 (E) under clean condition (0.30 g/L bovine albumin solution).

According to this suspension test, a disinfectant or a disinfectant solution at a particular concentration is considered as having virucidal activity if the virus titre is reduced by ≥4 $\log_{10}$ (inactivation ≥99.99 %) within the recommended exposure period, or ≥2 $\log_{10}$ (inactivation ≥99.00 %) for hygienic handwash only, within the recommended exposure period.

BerryC Sanitizer was examined at 20 °C at the concentration(s) of 100.00* % for the exposure time(s) of 0.5, 1, 5 and 30 minutes. After the exposure time(s), the viral reduction exceeded 4 $\log_{10}$-steps in all assays. According to the simple acceptance decision rule†, there is a minimal risk of false acceptance. Therefore, a virucidal activity against *Vaccinia virus*, strain Ankara, ATCC VR-1508 was measured as follows:

Clean condition	100.00** %	0.5 minute
Clean condition	100.00** %	1 minute
Clean condition	100.00** %	5 minutes
Clean condition	100.00** %	30 minutes

After evaluation with the *Vaccinia virus* strain Ankara, ATCC VR-1508, the disinfectant BerryC Sanitizer can be declared as having **'virucidal activity against all enveloped viruses'** according to EN 14476:2013+A2:2019. This declaration covers all enveloped viruses (Annex A), including blood-borne viruses HBV, HCV, HIV, as well as members of other virus families such as Orthomyxoviridae (including all human influenza viruses), Coronaviridae (such as MERS-CoV, SARS-CoV-1, and SARS-CoV-2).

Kuala Lumpur, 26 September 2025

Dr Syazani Suhaimi
Microbiologist

Dr Peter Cheong
Microbiologist

* Opinions and interpretations expressed here are outside the scope of SAMM (Laboratory Accreditation Scheme of Malaysia) accreditation.

** The product can only be tested at 80.00 % concentration or less, as some dilution always occurs when test organisms and interfering substance are added.

† The decision rule applied is simple acceptance rule with no guard band and up to 50 % risk of false acceptance or rejection. This rule has been determined by the laboratory and agreed with the client prior to testing.

Appendix 1

QAU CERTIFICATE*

The results stated in test report VX-TR-25-0454 dated 26 September 2025 were compared to the raw data of the tests and checked for correct transfer. No deviations were detected.

Kuala Lumpur, 26 September 2025

Dr Peter Cheong
Microbiologist

* Opinions and interpretations expressed here are outside the scope of SAMM (Laboratory Accreditation Scheme of Malaysia) accreditation.

Appendix 2 Raw data

Test Method	EN 14476:2013+A2:2019				**Titration Method**	Quantal test			
Product	BerryC Sanitizer				**Batch No.**	N/A			
Product Diluent	Hard water				**Lab No.**	VX-63-25-0002			
Test Organism	Vaccinia virus, strain Ankara, ATCC VR-1508				**Passage No.**	2			
Cell Line	BHK-21 cells, ATCC CCL-10				**Passage No.**	14			
Interfering Substance	0.30 g/L bovine albumin solution				**Inactivation Method**		Microspin column		
Test Temperature (°C)	20	**Incubation Temperature (°C)**		36	**Dilution Method**		Standard		
First Assay Test Date	19/09/2025	**Second Assay Test Date**	19/09/2025	**Analyzed By**	SSU	**Verified By**		PCH	

Validation and Control Procedures

	Product Concentration	Dilution	Dilution (log_{10}) 1	2	3	4	5	6	7	8	9	10	log_{10} $TCID_{50}$/ml	$\Delta TCID_{50}$ < 1 lg
Cell Susceptibility Control	PBS	Without	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 2 3 4 3 4 4	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	6.50 ± 0.00	Pass?
	100.00 %	1:10000	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 2 3 0 4 3 2 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	6.25 ± 0.33	**Yes**

	Product Concentration	Contact Time (minutes)	Dilution (log_{10}) 1	2	3	4	5	6	7	8	9	10	log_{10} $TCID_{50}$/ml	$\lvert TCID_{50} - V_C \rvert$ ≤ 0.5 lg
Suppression Efficiency Control	100.00 %	30	t t t t t t t t	t t t t t t t t	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 2 4 4 3 4	3 0 0 0 4 2 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	6.88 ± 0.37	Pass?
	Virus Control (V_C)	30	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 3 3 4 3 2 4	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	6.50 ± 0.00	**Yes**

	Product Concentration	Contact Time (minutes)	Dilution (log_{10}) 1	2	3	4	5	6	7	8	9	10	log_{10} $TCID_{50}$/ml	lg R = V_C - Na
Reference Test	0.70 % Formaldehyde	5	t t t t t t t t	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	3.50 ± 0.00	≥3.75 ± 0.44
		15	t t t t t t t t	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	3.50 ± 0.00	≥3.75 ± 0.44
	Virus Control (V_C)	0	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 2 4 4 4 4	4 3 0 0 3 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	6.88 ± 0.37	
		30	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 0 0 4 2 2 0	0 0 0 0 0 0 1 0	0 0 0 0 0 0 0 0	n.d	n.d	7.25 ± 0.44	
	Cytotoxicity Effect (CE)	-	t t t t t t t t	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	n.d	3.50 ± 0.00	

Appendix 2 Raw data

Test Procedure

	Product Concentration	Contact Time (minutes)	Dilution (log_{10}) 1	2	3	4	5	6	7	8	9	10	log_{10} $TCID_{50}$/ml	
First Assay (Na_1)	100.00 %	0.5	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	2.50 ± 0.00	V_{C1} - CE ≥ 4 Pass? **Yes**
	100.00 %	1	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	2.50 ± 0.00	
	100.00 %	5	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	2.50 ± 0.00	
	Virus Control (V_{C1})	0	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 2 4 4 4 4	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d.	n.d.	6.50 ± 0.00	
		30	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 3	2 0 0 0 0 0 0 0	0 0 0 0 0 0 1 0	0 0 0 0 0 0 0 0	n.d.	n.d.	6.75 ± 0.35	
	Cytotoxicity Effect (CE)	-	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	n.d	2.50 ± 0.00	

	Product Concentration	Contact Time (minutes)	Dilution (log_{10}) 1	2	3	4	5	6	7	8	9	10	log_{10} $TCID_{50}$/ml	
Second Assay (Na_2)	100.00 %	0.5	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	2.50 ± 0.00	V_{C2} - CE ≥ 4 Pass? **Yes**
	100.00 %	1	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	2.50 ± 0.00	
	100.00 %	5	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	2.50 ± 0.00	
	Virus Control (V_{C2})	0	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 3 4 4 4 3	4 0 0 0 3 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d.	n.d.	6.75 ± 0.33	
		30	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 3 4 4 3 4	3 4 0 0 2 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d.	n.d.	6.88 ± 0.37	
	Cytotoxicity Effect (CE)	-	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	n.d	2.50 ± 0.00	

Average Reduction (lg R)	Product Concentration	Contact Time (minutes)	First Assay (Na_1) log_{10} $TCID_{50}$/ml	lg R_1 = V_{C1} - Na_1	Second Assay (Na_2) log_{10} $TCID_{50}$/ml	lg R_2 = V_{C2} - Na_2	Average Reduction (lg R)
	100.00 %	0.5	≤2.50 ± 0.00	≥4.25 ± 0.35	≤2.50 ± 0.00	≥4.38 ± 0.37	≥4.32 ± 0.36
	100.00 %	1	≤2.50 ± 0.00	≥4.25 ± 0.35	≤2.50 ± 0.00	≥4.38 ± 0.37	≥4.32 ± 0.36
	100.00 %	5	≤2.50 ± 0.00	≥4.25 ± 0.35	≤2.50 ± 0.00	≥4.38 ± 0.37	≥4.32 ± 0.36

Appendix 2 Raw data

Test Procedure

	Product Concentration	Contact Time (minutes)	Dilution (log_{10}) 1	2	3	4	5	6	7	8	9	10	log_{10} $TCID_{50}$/ml	
First Assay (Na)	100.00 %	30	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	2.50 ± 0.00	V_{C1} - CE ≥ 4
														Pass?
	Virus Control (V_{C1})	0	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 2 4 4 4 4	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d.	n.d.	6.50 ± 0.00	**Yes**
		30	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 3	2 0 0 0 0 0 0 0	0 0 0 0 0 0 1 0	0 0 0 0 0 0 0 0	n.d.	n.d.	6.75 ± 0.35	
	Cytotoxicity Effect (CE)	–	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	n.d	2.50 ± 0.00	

	Product Concentration	Contact Time (minutes)	Dilution (log_{10}) 1	2	3	4	5	6	7	8	9	10	log_{10} $TCID_{50}$/ml	
Second Assay (Na2)	100.00 %	30	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	2.50 ± 0.00	V_{C2} - CE ≥ 4
														Pass?
	Virus Control (V_{C2})	0	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 3 4 4 4 3	4 0 0 0 3 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d.	n.d.	6.75 ± 0.33	**Yes**
		30	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 4 4 4 4 4	4 4 4 3 4 4 3 4	3 4 0 0 2 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d.	n.d.	6.88 ± 0.37	
	Cytotoxicity Effect (CE)	–	t t t t t t t t	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0	n.d	n.d	n.d	n.d	n.d	2.50 ± 0.00	

Average Reduction (lg R)	Product Concentration	Contact Time (minutes)	First Assay (Na_1) log_{10} $TCID_{50}$/ml	lg R_1 = V_{C1} - Na_1	Second Assay (Na_2) log_{10} $TCID_{50}$/ml	lg R_2 = V_{C2} - Na_2	Average Reduction (lg R)
	100.00 %	30	≤2.50 ± 0.00	≥4.25 ± 0.35	≤2.50 ± 0.00	≥4.38 ± 0.37	≥4.32 ± 0.36

Note

$TCID_{50}$: The dilution of the virus suspension that induces a CPE in 50 % of cell culture units

CPE: The morphological alteration of cells and/or their destruction caused by the cytopathic effect of virus multiplication. '0' denotes no CPE and '1' (approximately 25 % of cells) to '4' (all cells) denotes the degree of CPE per cell culture units.

V_C: log_{10} $TCID_{50}$ per ml in the viral test suspension at the beginning and at the maximum contact time

N_a: log_{10} $TCID_{50}$ per ml in the test mixture at the end of the contact time

CE: The morphological alteration of cells caused by the cytotoxicity effect of the product test solution. 't' denotes the presence of cytotoxicity per cell culture units.

A: log_{10} $TCID_{50}$ per ml in the cell susceptibility control as compared to PBS

B: log_{10} $TCID_{50}$ per ml in the suppression efficiency control as compared to the virus control

C: log_{10} $TCID_{50}$ per ml in the reference test for virus inactivation after 30 and 60 minutes (5 and 15 minutes for vaccinia virus)

EN 14476:2013+A2:2019 Annex A

List of viruses from different parts of human body, which may contaminate hands, surgical instruments, surfaces and textiles.
Note: Enveloped viruses are in bold. This list is not exhaustive.

Blood
Enterovirus
Filoviridae
Flavivirus
Herpesviridae
Hepatitis A Virus (HAV)
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Hepatitis Delta virus (HDV)
Human Immunodeficiency Virus (HIV)
Human T Cell Leukemia Virus (HTLV)
Parvovirus B 19

Respiratory tract
Adenovirus (Mast-)
Coronavirus
Enterovirus
Herpesviridae
Influenza Virus
Paramyxoviridae
Rhinovirus
Rubella Virus

Neuronal tissue, ear & nose, eye
Adenovirus (Mast-)
Enterovirus
Herpesviridae
Measles Virus
Human Immunodeficiency Virus (HIV)
Polyomavirus
Rabies Virus
Rubella Virus

Gastro-intestinal
Adenovirus(Mast-)
Caliciviridae
Coronavirus
Astrovirus
Enterovirus
Hepatitis A Virus (HAV)
Hepatitis E Virus (HEV)
Rotavirus

Skin, breast and/or milk
Enterovirus
Herpesviridae
Human Immunodeficiency Virus (HIV)
Human T Cell Leukemia Virus (HTLV)
Papillomavirus
Poxviridae

Spleen and lymph nodes (see also “Blood“)
Human T Cell Leukemia Virus (HTLV)
Human Immunodeficiency Virus (HIV)

Dental procedure
Adenovirus(Mast-)
Enterovirus
Herpesviridae
Hepatitis B virus (HBV)
Hepatitis C Virus (HCV)
Hepatitis Delta Virus (HDV)
Human Immunodeficiency Virus (HIV)

Urogenital tract

Hepatitis B Virus (HBV)
Herpesviridae
Human Immunodeficiency Virus (HIV)
Human T Cell Leukemia Virus (HTLV)
Papillomavirus
Polyomavirus

Reference:

Van Regenmortel MHV et al. Eds.: Virus Taxonomy, Classification and Nomenclature of Viruses, seventh report of the international committee on taxonomy of viruses. Academic Press, San Diego, 2000.

VIROXY LABS

Looking to Add More Efficacy Claims?

Call us at +60 (0)3 2630 8888.
We have over 160 test microorganisms to choose from.